|
|
|
|
EXPEDITION-4: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR (ABT-493/ABT-530) IN PATIENTS WITH RENAL IMPAIRMENT AND CHRONIC HEPATITIS C VIRUS GENOTYPE 1 - 6 INFECTION
|
|
|
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Ed Gane1, Eric Lawitz2, David Pugatch3, Georgios Papatheodoridis4, Norbert Bräu5, Ashley Brown6, Stanislas Pol7, Vincent Leroy8, Marcello Persico9, Christophe Moreno10, Massimo Colombo11, Eric M Yoshida12, David R Nelson13, Yang Lei3, Matthew Kosloski3, Federico Mensa3
1Liver Unit, Auckland City Hospital, Auckland, New Zealand; 2The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 3AbbVie Inc, North Chicago, IL, USA; 4Academic Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece; 5James J. Peters VA Medical Center, Bronx, NY and Icahn School of Medicine at Mount Sinai, New York, NY; 6Imperial College Healthcare, London, UK; 7Groiupe Hospitalier Cochin-Saint Vincent De Paul, Paris, France; 8Centre Hospitalier Universitaire de Grenoble, Grenoble, France; 9Internal Medicine and Hepatology Unit, University of Salerno, Italy; 10CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; 11Ospedale Maggiore Policlinico, University of Milan, Milan, Italy; 12University of British Columbia, Vancouver, BC, Canada; 13Department of Medicine, University of Florida, Gainesville, FL, USA
|
|
|
|
|
|
|